fluocinolone acetonide has been researched along with Panuveitis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, PY | 1 |
| Cai, CX; Grewal, DS; Jaffe, GJ; Keenan, RT; Skalak, C | 1 |
| Lin, P; Thomas, AS | 1 |
| Jaffe, GJ; Pavesio, CE | 1 |
| Altaweel, MM; Ansari, H; Dunn, JP; Elner, SG; Friedman, DS; Holbrook, JT; Jabs, DA; Kempen, JH; Lim, LL; Sugar, EA; Van Natta, ML | 1 |
| Agrawal, R | 1 |
| Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE | 1 |
| Almanzor, R; Frick, KD; Holbrook, JT; Holland, GN; Jabs, DA; Sugar, EA; Thorne, JE; Venugopal, V; Wang, RC | 1 |
| Agarwal, M; Mayor, R; Shrivastav, A; Singh, S; Venkatesh, R | 1 |
| Burkholder, BM; Dunn, JP; Nguyen, QD; Thorne, JE; Wang, J | 1 |
| Acharya, NR; Altaweel, MM; Dunn, JP; Elner, SG; Jaffe, GJ; Kempen, JH; Lightman, SL; Sugar, EA; Thorne, JE; Vitale, AT | 1 |
| Altaweel, MM; Burke, AE; Drye, LT; Frick, KD; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE | 1 |
| Boonsopon, S; Dhanireddy, S; Foster, CS; Freitas-Neto, CA; Maghsoudlou, A; Payal, A; Ratwatte, MD | 1 |
| Altaweel, MM; Drye, LT; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE | 1 |
| Ashton, P; Jaffe, GJ; Keenan, RT; Lin, P; Skalak, C; Stinnett, SS | 1 |
| Stewart, JM; Wan, W | 1 |
| Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE | 1 |
1 review(s) available for fluocinolone acetonide and Panuveitis
| Article | Year |
|---|---|
Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
Topics: Anti-Infective Agents; Drug Implants; Eye Infections, Bacterial; Fluocinolone Acetonide; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Panuveitis; Rituximab; Sirolimus; Uveitis, Intermediate; Uveitis, Posterior | 2020 |
10 trial(s) available for fluocinolone acetonide and Panuveitis
| Article | Year |
|---|---|
Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
Topics: Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Male; Middle Aged; Panuveitis; Prospective Studies; Recurrence; Time Factors; Tomography, Optical Coherence; Uveitis, Posterior; Visual Acuity | 2020 |
Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Topics: Adult; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glaucoma; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Male; Middle Aged; Panuveitis; Prospective Studies; Risk Factors; Treatment Outcome; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Vitreous Body | 2020 |
Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
Topics: Adult; Anti-Inflammatory Agents; Australia; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Humans; Immunosuppression Therapy; Intravitreal Injections; Male; Middle Aged; Panuveitis; Quality of Life; Time Factors; Treatment Outcome; United Kingdom; United States; Uveitis; Visual Acuity | 2017 |
Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
Topics: Adult; Aged; Cohort Studies; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Health Status; Humans; Male; Middle Aged; Panuveitis; Quality of Life; Risk Factors; Sickness Impact Profile; Surveys and Questionnaires; Uveitis, Intermediate; Uveitis, Posterior; Vision, Ocular; Visual Acuity; Visual Fields | 2017 |
Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.
Topics: Capillary Permeability; Cross-Sectional Studies; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Panuveitis; Retina; Retinal Vessels; Sensitivity and Specificity; Tomography, Optical Coherence; Uveitis, Intermediate; Uveitis, Posterior | 2013 |
Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
Topics: Adult; Anti-Inflammatory Agents; Cost-Benefit Analysis; Drug Implants; Fluocinolone Acetonide; Health Care Costs; Humans; Panuveitis; Quality-Adjusted Life Years; United States; Uveitis, Intermediate; Uveitis, Posterior | 2014 |
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up
Topics: Adult; Aged; Anti-Inflammatory Agents; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Panuveitis; Prednisone; Tomography, Optical Coherence; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Visual Fields | 2015 |
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen
Topics: Adult; Aged; Anti-Inflammatory Agents; Cataract; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Male; Middle Aged; Panuveitis; Prednisone; Prospective Studies; Quality of Life; Risk Factors; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity | 2015 |
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Topics: Adult; Anti-Inflammatory Agents; Delayed-Action Preparations; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Male; Middle Aged; Panuveitis; Prospective Studies; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Young Adult | 2016 |
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
Topics: Drug Implants; Drug Therapy, Combination; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Panuveitis; Prednisone; Quality of Life; Sickness Impact Profile; Treatment Outcome; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Visual Fields | 2011 |
7 other study(ies) available for fluocinolone acetonide and Panuveitis
| Article | Year |
|---|---|
Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity.
Topics: Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Male; Panuveitis; Uveitis, Posterior; Vitreous Body | 2022 |
Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
Topics: Adult; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Panuveitis; Recurrence; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity | 2020 |
Re: Jaffe et al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results (Ophthalmology. 2016;123:1940-1948).
Topics: Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Panuveitis; Uveitis; Uveitis, Intermediate; Uveitis, Posterior | 2017 |
Re: Jaffe et al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: 2-year results (Ophthalmology. 2016;123:1940-1948).
Topics: Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Panuveitis; Uveitis; Uveitis, Intermediate; Uveitis, Posterior | 2017 |
Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.
Topics: Adult; Aged; Aged, 80 and over; Birdshot Chorioretinopathy; Chorioretinitis; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Male; Middle Aged; Panuveitis; Postoperative Complications; Postoperative Period; Retrospective Studies; Treatment Outcome; Uveitis, Posterior; Visual Acuity | 2013 |
Outcome of Multiple Implants and Dissociation of Fluocinolone Acetonide Intravitreal Implant (Retisert) in a Series of 187 Consecutive Implants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Panuveitis; Retrospective Studies; Treatment Outcome; Vitreous Body; Young Adult | 2015 |
Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal.
Topics: Adult; Anti-Inflammatory Agents; Cadaver; Device Removal; Drug Implants; Female; Fluocinolone Acetonide; Foreign-Body Migration; Humans; In Vitro Techniques; Infusions, Intralesional; Panuveitis; Pressure | 2011 |